RNU6-551P

Across TCGA pan-cancer cohorts, RNU6-551P RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RNU6-551P data layer.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher RNU6-551P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-551P expression acts as an unfavorable survival marker.

PRAD and SARC are the cancer types where RNU6-551P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Tertile	All	0.154	0.777	<.001	18	view →
SARC	OS	Tertile	All	0.201	0.766	.007	18	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RNU6-551P–PRAD (DFS)

Open the PRAD breakdown →